Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Axitinib in High-Risk Renal Cell Carcinoma
NCT01599754Phase 3Terminated
- Sponsor
- SFJ Pharmaceuticals
- Start
- Apr 2012
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Axitinib with Placebo (2 arms). Primary endpoint: Disease Free Survival at 5 years. Started Apr 2012; status: terminated.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01599754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01599754.